Jade Biosciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell JBIO and other ETFs, options, and stocks.

About JBIO

Jade Biosciences, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. 

CEO
Tom Frohlich
CEOTom Frohlich
Employees
55
Employees55
Headquarters
Waltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded
2018
Founded2018
Employees
55
Employees55

JBIO Key Statistics

Market cap
875.89M
Market cap875.89M
Price-Earnings ratio
-5.94
Price-Earnings ratio-5.94
Dividend yield
Dividend yield
Average volume
859.71K
Average volume859.71K
High today
$19.43
High today$19.43
Low today
$17.31
Low today$17.31
Open price
$19.01
Open price$19.01
Volume
993.28K
Volume993.28K
52 Week high
$28.00
52 Week high$28.00
52 Week low
$6.57
52 Week low$6.57

Stock Snapshot

The current Jade Biosciences(JBIO) stock price is $17.75, with a market capitalization of 875.89M. The stock trades at a price-to-earnings (P/E) ratio of -5.94.

On 2026-06-03, Jade Biosciences(JBIO) stock moved within a range of $17.31 to $19.43. With shares now at $17.75, the stock is trading +2.5% above its intraday low and -8.6% below the session's peak.

Trading volume for Jade Biosciences(JBIO) stock has reached 993.28K, versus its average volume of 859.71K.

Over the past 52 weeks, Jade Biosciences(JBIO) stock has traded between a high of $28.00 and a low of $6.57.

Over the past 52 weeks, Jade Biosciences(JBIO) stock has traded between a high of $28.00 and a low of $6.57.

JBIO News

TipRanks 1d
Akash Tewari Initiates Buy on JBIO, Citing Strong Early JADE101 Data, Clean Safety Profile, and Significant IgA Nephropathy Commercial Upside

Akash Tewari, an analyst from Jefferies, maintained the Buy rating on Jade Biosciences. The associated price target is $40.00. Unlock trusted, data-backed inve...

TipRanks 5d
Jade Biosciences’ JADE101 Trial Opens a New Front in IgA Nephropathy Investing

Jade Biosciences, Inc. (JBIO) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from anal...

Analyst ratings

100%

of 10 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own JBIO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.